{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:41:09Z","timestamp":1787737269097,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019214","name":"l\u00e9ka\u0159sk\u00e1 fakulta Univerzity Karlovy","doi-asserted-by":"publisher","award":["UNCE\/MED\/007"],"award-info":[{"award-number":["UNCE\/MED\/007"]}],"id":[{"id":"10.13039\/100019214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["LX22NPO5107"],"award-info":[{"award-number":["LX22NPO5107"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["LX22NPO5104"],"award-info":[{"award-number":["LX22NPO5104"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NU21-08\\u201300324"],"award-info":[{"award-number":["NU21-08\\u201300324"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cca.2024.119824","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T15:37:33Z","timestamp":1718811453000},"page":"119824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["LysoGb3 quantification facilitates phenotypic categorization of Fabry disease patients: Insights gained by a novel MS\/MS method"],"prefix":"10.1016","volume":"561","author":[{"given":"Ladislav","family":"Kuchar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Berna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Poupetova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ledvinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Dostalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Reichmannova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Befekadu","family":"Asfaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cca.2024.119824_b0005","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2024.119824_b0010","unstructured":"O. Lidove, R. Jaussaud, S. Aractingi, Dermatological and soft-tissue manifestations of Fabry disease: characteristics and response to enzyme replacement therapy, in: A. Mehta, M. Beck, G. Sunder-Plassmann (Eds.), Fabry Disease: Perspectives from 5 Years of FOS, Oxford, 2006."},{"issue":"8","key":"10.1016\/j.cca.2024.119824_b0015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J. Mol. Med. (berl)"},{"issue":"12","key":"10.1016\/j.cca.2024.119824_b0020","doi-asserted-by":"crossref","first-page":"e0260601","DOI":"10.1371\/journal.pone.0260601","article-title":"National Stroke Research Network, C.S. Czech Neurological Society, Nationwide screening for Fabry disease in unselected stroke patients","volume":"16","author":"Tomek","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cca.2024.119824_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107585","article-title":"An expert consensus on the recommendations for the use of biomarkers in Fabry disease","volume":"139","author":"Burlina","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.cca.2024.119824_b0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.cca.2024.119824_b0035","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ajmg.a.32712","article-title":"Prosaposin deficiency and saposin B deficiency (activator-deficient metachromatic leukodystrophy): report on two patients detected by analysis of urinary sphingolipids and carrying novel PSAP gene mutations","volume":"149A","author":"Kuchar","year":"2009","journal-title":"Am. J. Med. Genet. A"},{"issue":"24","key":"10.1016\/j.cca.2024.119824_b0040","doi-asserted-by":"crossref","first-page":"13382","DOI":"10.1021\/acs.analchem.7b03609","article-title":"Separation and analysis of lactosylceramide, galabiosylceramide, and globotriaosylceramide by LC-MS\/MS in urine of Fabry disease patients","volume":"89","author":"Boutin","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2024.119824_b0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.acc.2016.06.004","article-title":"Tandem mass spectrometry of sphingolipids: applications for diagnosis of sphingolipidoses","volume":"77","author":"Kuchar","year":"2016","journal-title":"Adv. Clin. Chem."},{"issue":"4","key":"10.1016\/j.cca.2024.119824_b0050","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.cca.2024.119824_b0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ab.2017.02.019","article-title":"Quantitation of plasmatic lysosphingomyelin and lysosphingomyelin-509 for differential screening of Niemann-Pick A\/B and C diseases","volume":"525","author":"Kuchar","year":"2017","journal-title":"Anal. Biochem."},{"issue":"7","key":"10.1016\/j.cca.2024.119824_b0060","doi-asserted-by":"crossref","first-page":"e0181700","DOI":"10.1371\/journal.pone.0181700","article-title":"LC-MS\/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease","volume":"12","author":"Pettazzoni","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cca.2024.119824_b0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/EBC20190090","article-title":"Lyso-glycosphingolipids: presence and consequences","volume":"64","author":"van Eijk","year":"2020","journal-title":"Essays Biochem."},{"key":"10.1016\/j.cca.2024.119824_b0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.01.018","article-title":"Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation","volume":"466","author":"Auray-Blais","year":"2017","journal-title":"Clin. Chim. Acta"},{"issue":"23","key":"10.1016\/j.cca.2024.119824_b0075","article-title":"Tandem Mass Spectrometry Quantitation of Lyso-Gb3 and six related analogs in plasma for Fabry disease patients","volume":"17","author":"Boutin","year":"2016","journal-title":"Curr. Protoc. Hum. Genet. 90"},{"issue":"12","key":"10.1016\/j.cca.2024.119824_b0080","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1515\/cclm-2018-1301","article-title":"Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study","volume":"57","author":"Polo","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"issue":"8","key":"10.1016\/j.cca.2024.119824_b0085","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"1","key":"10.1016\/j.cca.2024.119824_b0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.cca.2024.119824_b0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4196\/kjpp.2023.27.3.231","article-title":"Lyso-globotriaosylsphingosine induces endothelial dysfunction via autophagy-dependent regulation of necroptosis","volume":"27","author":"Hwang","year":"2023","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"10.1016\/j.cca.2024.119824_b0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cca.2015.11.018","article-title":"Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients","volume":"452","author":"Abaoui","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2024.119824_b0105","doi-asserted-by":"crossref","unstructured":"G.V. Baydakova, A.A. Ilyushkina, S. Moiseev, I.O. Bychkov, N.V. Nikitina, C.A.C. Buruleva capital Te, E.Y. Zakharova, alpha-Galactosidase A\/lysoGb3 ratio as a potential marker for Fabry disease in females, Clin Chim Acta 501 (2020) 27-32.","DOI":"10.1016\/j.cca.2019.10.031"},{"issue":"1","key":"10.1016\/j.cca.2024.119824_b0110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/cimb43010032","article-title":"Plasma Globotriaosylsphingosine and alpha-Galactosidase A Activity as a Combined Screening Biomarker for Fabry Disease in a Large Japanese Cohort","volume":"43","author":"Maruyama","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"issue":"2","key":"10.1016\/j.cca.2024.119824_b0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin Chim Acta"},{"issue":"7","key":"10.1016\/j.cca.2024.119824_b0120","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/ajmg.a.62728","article-title":"Pitfalls of X-chromosome inactivation testing in females with Fabry disease","volume":"188","author":"Reboun","year":"2022","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.cca.2024.119824_b0125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfl528","article-title":"A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population","volume":"22","author":"Merta","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.cca.2024.119824_b0130","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinbiochem.2004.11.007","article-title":"Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry","volume":"38","author":"Taylor","year":"2005","journal-title":"Clin Biochem"},{"issue":"4","key":"10.1016\/j.cca.2024.119824_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043223","article-title":"Mass spectrometry analysis of globotriaosylsphingosine and its analogues in dried blood spots","volume":"24","author":"Boutin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2024.119824_b0140","article-title":"A new multiplex analysis of glucosylsphingosine and globotriaosylsphingosine in dried blood spots by tandem mass spectrometry","volume":"37","author":"Van Baelen","year":"2023","journal-title":"Mol Genet Metab Rep"},{"issue":"7","key":"10.1016\/j.cca.2024.119824_b0145","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb(3)-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal Chem"},{"key":"10.1016\/j.cca.2024.119824_b0150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC-MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"Boutin","year":"2012","journal-title":"Clin Chim Acta"},{"issue":"3","key":"10.1016\/j.cca.2024.119824_b0155","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2024.119824_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100138","article-title":"Recommendations for good practice in MS-based lipidomics","volume":"62","author":"Kofeler","year":"2021","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.cca.2024.119824_b0165","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1194\/jlr.D800051-JLR200","article-title":"Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers","volume":"50","author":"Shaner","year":"2009","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.cca.2024.119824_b0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","volume":"41","author":"Burlina","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.cca.2024.119824_b0175","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00219337","article-title":"Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease","volume":"88","author":"Leinekugel","year":"1992","journal-title":"Hum Genet"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989812402076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989812402076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T11:44:06Z","timestamp":1720957446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000989812402076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":35,"alternative-id":["S000989812402076X"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.119824","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LysoGb3 quantification facilitates phenotypic categorization of Fabry disease patients: Insights gained by a novel MS\/MS method","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.119824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119824"}}